Expression of Urokinase-Type Plasminogen Activator and Its Receptor in Gastric Fibroblasts and Effects of Nonsteroidal Antiinflammatory Drugs and Prostaglandin

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Digestive Diseases and Sciences

• Publication date

  2003-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1023/B:DDAS.0000007859.10680.b1PMID 14714609
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Extracellular matrix destruction by invasive tumor cells

  2004cited by this paper
• Urokinase type plasminogen activator and its receptor regulate the invasive potential of gastric cancer cell lines.

  2000cited by this paper
• The effect of NSAIDs and a COX‐2 specific inhibitor on Helicobacter pylori‐induced PGE2 and HGF in human gastric fibroblasts

  2000cited by this paper
• Localisation of cyclooxygenase 1 and cyclooxygenase 2 inHelicobacter pylori related gastritis and gastric ulcer tissues in humans

  2000cited by this paper
• Selective cyclooxygenase-2 inhibitors.

  1999cited by this paper
• Selective cyclo‐oxygenase‐2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach

  1998cited by this paper
• Nonsteroidal anti-inflammatory drugs may delay the repair of gastric mucosa by suppressing prostaglandin-mediated increase of hepatocyte growth factor production.

  1998cited by this paper
• Increased secretion of urokinase-type plasminogen activator by human lung microvascular endothelial cells.

  1998cited by this paper
• Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.

  1998cited by this paper
• High level of urokinase‐type plasminogen activator is a new prognostic marker in patients with gastric carcinoma

  1997cited by this paper
• Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer.

  1997cited by this paper
• Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice.

  1997cited by this paper
• The prognostic impact of the urokinase-type plasminogen activator system is associated with tumour differentiation in gastric cancer.

  1996cited by this paper
• Hepatocyte growth factor as a key to modulate anti-ulcer action of prostaglandins in stomach.

  1996influential reference
• Plasminogen activators and matrix metalloproteinases in angiogenesis.

  1996cited by this paper
• Expression of urokinase‐type plasminogen activator and plasminogen activator inhibitor in colon disease

  1995cited by this paper
• Biological Activation of pro-HGF (Hepatocyte Growth Factor) by Urokinase Is Controlled by a Stoichiometric Reaction (*)

  1995influential reference
• Reduced tissue type plasminogen activator activity of the gastroduodenal mucosa in peptic ulcer disease.

  1993cited by this paper
• Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor.

  1992influential reference
• Urokinase‐plasminogen activator in breast cancer: assay by both catalytic and immunoassay

  1991cited by this paper
• The plasminogen activator/plasmin system.

  1991cited by this paper
• Tumor necrosis factor induction of urokinase-type plasminogen activator in human endothelial cells.

  1991cited by this paper
• Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo.

  1990cited by this paper
• The urokinase type of plasminogen activator in cancer of digestive tracts.

  1988cited by this paper
• Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use.

  1987cited by this paper
• Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors

  1987cited by this paper
• Plasminogen activators, tissue degradation, and cancer.

  1985cited by this paper
• Effect of indomethacin, tiaprofenic acid and dicrofenac on rat gastric mucosal damage and content of prostacyclin and prostaglandin E2.

  1985cited by this paper
• Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane.

  1981cited by this paper
• Cytoprotection by prostaglandins.

  1979cited by this paper
• Upper gastrointestinal disease in rheumatoid arthritis

  1974cited by this paper
• Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.

  1971cited by this paper

• A comprehensive review on rhubarb astringent/ laxative actions and the role of aquaporins as hub genes

  2022cites this paper
• Relevance of the plasminogen activation system in the pathogenesis and progression of gastric cancer

  2018cites this paper
• Effect of body-weight loading onto the articular cartilage on the occurrence of quinolone-induced chondrotoxicity in juvenile rats.

  2013cites this paper
• The role of plasminogen activator inhibitor-1 in gastric mucosal protection

  2013cites this paper
• Tumor necrosis factor α stimulates expression and secretion of urokinase plasminogen activator in human dental pulp cells.

  2012cites this paper
• The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice.

  2010cites this paper
• Effects of Simulated Bleeding in an in Vitro Nasal Fibroblast Wound Healing Model

  2010cites this paper
• Effect of prostaglandin E2 on urokinase‐type plasminogen activator production by human lung fibroblasts

  2009cites this paper
• The ovine urokinase plasminogen activator and its receptor cDNAs: molecular cloning, characterization and expression in various tissues.

  2009cites this paper
• Inhibition of the healing of gastric ulcer by glucocorticoid and its relation to proinflammatory cytokines.

  2009cites this paper
• The Effects of Cyclooxygenase2–ProstaglandinE2 Pathway on Helicobacter pylori‐Induced Urokinase‐Type Plasminogen Activator System in the Gastric Cancer Cells

  2008cites this paper
• IL-1β stimulates urokinase-type plasminogen activator expression and secretion in human dental pulp cells

  2007cites this paper
• The IL-1 type 1 receptor is required for the development of LPS-induced airways disease.

  2007cites this paper
• IL-1beta stimulates urokinase-type plasminogen activator expression and secretion in human dental pulp cells.

  2007cites this paper
• [Gastropathy caused by nonsteriod anti-inflammatory drugs: from understanding of development mechanisms to planning strategy of treatment and prophylaxis].

  2007cites this paper
• Tissue-type plasminogen activator activity in morphologically normal tissues adjacent to gastrointestinal carcinomas is associated with the degree of tumor progression

  2006cites this paper
• Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori

  2005cites this paper
• Preservation of the Characteristics of the Cultured Human Type II Alveolar Epithelial Cells

  2004cites this paper